Notice Regarding Business Alliance With BSMO Co., Ltd. and SBI Africa Co., Ltd.
1.2.2021 03:30:00 EET | Business Wire | Press release
BSMO Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director: Tadashi Shimizu, hereinafter "BSMO") has announced today that BSMO has entered into a business alliance agreement with SBI Africa Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director: Tomoya Kitagawa, hereinafter "SBI Africa").
1. Background
As a pioneer in the field of SNS marketing, BSMO, through the best use of D2C x SNS marketing expertise and technology, provides one-stop growth hacking services for D2C e-commerce companies and helps deliver high-quality Japanese products and services to the world.
The population of Africa, where many emerging countries are located, is expected to double from 1.06 billion in 2019 to 2.11 billion people in 2050, according to the latest United Nations projections.
With the rapid population growth and economic growth in the African countries, the automobile usage rate is increasing every year which is driving a strong demand for reliable and affordable used cars from Japan.
By forming a business alliance with SBI Africa, which exports Japanese used cars to emerging countries, BSMO will introduce its D2C x SNS marketing expertise and technology to the SBI Group in order to strengthen the D2C exports in Africa, and thus improve the profitability and corporate values of both parties.
2. Details of the Business Alliance
(1) Improving the quality of SBI Africa's products and services by providing marketing research, advertising strategies, measurement strategies, design strategies, AI analytics, operations services and customer support services.
(2) Improving the profitability and brand value of both parties in the African region through joint sales of BSMO affiliated products and services on SBI Africa’s cross-border e-commerce website.
(3) Jointly providing system development and marketing strategy services for Japanese companies operating in Africa.
(4) Improving the profitability of BSMO and the marketing capabilities of SBI Group, through BSMO’s introduction of its marketing expertise and technology to SBI Group, etc.
[Company Overview]
|
Name |
BSMO Co., Ltd. |
|
Location |
1-17-1 Toranomon, Minato-ku, Tokyo Toranomon Hills Business Tower 14th floor |
|
Representative |
Tadashi Shimizu |
|
Business Description |
D2C marketing business, global growth hack business using SNS, branding business, media business, system development business, artificial intelligence (AI) development business, etc. |
|
Name |
SBI Africa Co., Ltd. |
|
Location |
1-6-1 Roppongi, Minato-ku, Tokyo Izumi Garden Tower 15F |
|
Representative |
Tomoya Kitagawa |
|
Business Description |
Overseas export business of domestic used cars, financial service provision business in partnership with overseas financial institutions, venture capital investment targeting the African region, etc. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210131005005/en/
Contact information
For inquiries regarding this press release:
BSMO Co., Ltd. +81-3-6459-5712
Ai Sena, Junko Nakahara
SBI Africa Co., Ltd. +81-3-6229-0086
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom